1
|
Afifi NM, Anisimov SV, Aguilar-Quesada R, Kinkorova J, Marrs S, Nassimbwa S, Kozlakidis Z, Parry-Jones A. Biobanking Spotlight on Europe, Middle East, and Africa: Presenting the Collective Experience of the ISBER-EMEA Regional Ambassadors. Biopreserv Biobank 2020; 18:471-478. [PMID: 32780585 DOI: 10.1089/bio.2020.0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | - Judita Kinkorova
- Faculty of Medicine, University Hospital in Pilsen and Charles University, Pilsen, Czech Republic
| | | | | | - Zisis Kozlakidis
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Alison Parry-Jones
- Wales Cancer Bank, Cardiff University School of Medicine, College of Biomedical and Life Sciences, Cardiff, United Kingdom
| |
Collapse
|
2
|
Simanek V, Topolcan O, Karlikova M, Dolejsova O, Fuchsova R, Kinkorova J, Slouka D, Kucera R. Stability of total prostate-specific antigen and free prostate-specific antigen after 10 years’ storage. Int J Biol Markers 2018; 33:463-466. [DOI: 10.1177/1724600818789414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction: PSA is a serine protease composed of 240 amino acids in a single polypeptide chain and is a routine parameter in prostate cancer diagnostics. The aim of our study was to test the long-term stability of tPSA and fPSA after 10 years’ storage at −80°C. Materials and methods: We analyzed two aliquots from 55 serum samples. The first was assayed in routine testing at the time of establishing the diagnosis. The second was thawed for further testing after approximately 10 years’ storage at −80°C. The mean of storage time was 10.41 years (min–max: 9.35–11.40 years). We compared the results of tPSA and fPSA. We calculated the fPSA/tPSA ratio and compared the results of clinical evaluation. Serum tPSA and fPSA levels were assayed using chemiluminescent kits Access Hybritech PSA and free PSA. All measurements were performed using the instrument UniCel® DxI 800. Results: tPSA decreased 3.59% on average with a correlation r=0.9213, and fPSA increased at an average of 2.41% with a correlation r=0.9338. The fPSA/tPSA ratio increased 0.80% on average with a correlation r=0.9174. On clinical evaluation, five samples had fallen to a less malignant category and three samples had risen to a higher malignant category compared with the original results. Conclusion: The stability of tPSA and fPSA levels in serum is sufficient after 10 years’ storage at −80°C. Calculation of the fPSA/tPSA ratio is not recommended due to the change in the category of malignancy of 15% of the samples.
Collapse
Affiliation(s)
- Vaclav Simanek
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - Ondrej Topolcan
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - Marie Karlikova
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - Olga Dolejsova
- Department of Urology, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - Radka Fuchsova
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - Judita Kinkorova
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - David Slouka
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| | - Radek Kucera
- Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Czech Republic
| |
Collapse
|
3
|
Kucera R, Topolcan O, Fiala O, Kinkorova J, Treska V, Zedníková I, Slouka D, Simanek V, Safanda M, Babuska V. The Role of TPS and TPA in the Diagnostics of Distant Metastases. Anticancer Res 2016; 36:773-777. [PMID: 26851038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
AIM The aim of the study was to assess the degree to which tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS), as well as carcinoembryonic antigen (CEA), can assist in the detection of distant metastases. PATIENTS AND METHODS We assessed 157 patients with colorectal and breast cancer divided into two groups. The first was a group of patients with cancer at stages 1, 2 and 3; the second was a group of patients with cancer at stage 4 with metastasis. RESULTS We found significantly higher levels of all biomarkers in the metastatic group compared to the group with cancer at stages 1-3 (p<0.0001). The calculated area under the receiver operating characteristic (ROC) curve was 0.9929 for TPS, 0.9337 for TPA and 0.7234 for CEA. The cut-off was calculated for each biomarker at 95% specificity, TPS cut-off=255 IU/l (sensitivity 95%), TPA cut-off=200 IU/l (sensitivity 70%) and CEA cut-off=18 μg/l (sensitivity 37%). CONCLUSION We suggest combining CEA with TPS or TPA in the detection of distant metastases or using only cytokeratins. This approach can significantly increase the quality of detection of the metastatic process.
Collapse
Affiliation(s)
- Radek Kucera
- Laboratory of Immunoanalysis, Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Ondrej Topolcan
- Laboratory of Immunoanalysis, Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Ondrej Fiala
- Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Medical School in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Judita Kinkorova
- Laboratory of Immunoanalysis, Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Vladislav Treska
- Department of Surgery, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Ilona Zedníková
- Department of Surgery, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - David Slouka
- Laboratory of Immunoanalysis, Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Vaclav Simanek
- Laboratory of Immunoanalysis, Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Martin Safanda
- Laboratory of Immunoanalysis, Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Vaclav Babuska
- Department of Medical Chemistry and Biochemistry, Medical School in Pilsen, Charles University in Prague, Prague, Czech Republic
| |
Collapse
|
4
|
Brunner-La Rocca HP, Fleischhacker L, Golubnitschaja O, Heemskerk F, Helms T, Hoedemakers T, Allianses SH, Jaarsma T, Kinkorova J, Ramaekers J, Ruff P, Schnur I, Vanoli E, Verdu J, Zippel-Schultz B. Challenges in personalised management of chronic diseases-heart failure as prominent example to advance the care process. EPMA J 2016; 7:2. [PMID: 26913090 PMCID: PMC4765020 DOI: 10.1186/s13167-016-0051-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 12/15/2015] [Indexed: 12/31/2022]
Abstract
Chronic diseases are the leading causes of morbidity and mortality in
Europe, accounting for more than 2/3 of all death causes and 75 % of the healthcare
costs. Heart failure is one of the most prominent, prevalent and complex chronic
conditions and is accompanied with multiple other chronic diseases. The current
approach to care has important shortcomings with respect to diagnosis, treatment and
care processes. A critical aspect of this situation is that interaction between
stakeholders is limited and chronic diseases are usually addressed in
isolation. Health care in Western countries requires an innovative approach to
address chronic diseases to provide sustainability of care and to limit the
excessive costs that may threaten the current systems. The increasing prevalence of
chronic diseases combined with their enormous economic impact and the increasing
shortage of healthcare providers are among the most critical threats. Attempts to
solve these problems have failed, and future limitations in financial resources will
result in much lower quality of care. Thus, changing the approach to care for
chronic diseases is of utmost social importance.
Collapse
Affiliation(s)
- Hans-Peter Brunner-La Rocca
- Heart Failure Clinic, Department of Cardiology, Maastricht University Medical Center, PO Box 5800, 6202AZ Maastricht, The Netherlands
| | | | | | | | - Thomas Helms
- German Foundation for the Chronically Ill, Fürth, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kucera R, Topolcan O, Treskova I, Kinkorova J, Windrichova J, Fuchsova R, Svobodova S, Treska V, Babuska V, Novak J, Smejkal J. Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. Anticancer Res 2015; 35:3537-3541. [PMID: 26026122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM The aim of the present study was to evaluate the usefulness of four interleukins (IL-2, IL-6, IL-8 and IL-10) for melanoma detection and correlate these interleukins with sentinel node metastasis positivity. PATIENTS AND METHODS A group of 236 persons was assessed: 175 patients with melanomas and 61 healthy persons. Melanoma patients were divided to four groups according to Breslow score. We determined IL-2, IL-6, IL-8 and IL-10 in each plasma sample. Interleukin plasma levels were assayed using a Human Cytokine Milliplex Map kit. Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader. Plasma samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. RESULTS We compared interleukin plasma levels in the healthy group and plasma levels in each Breslow score stage. In the first Breslow score stage, IL-2 (p<0.0001), IL-6 (p=0.0004) and IL-10 (p<0.0001) were positive. In the second Breslow score, stage IL-2 (p<0.0001), IL-6 (p<0.0001), IL-8 (p=0.0017) and IL-10 (p<0.0001) were positive. By comparing the group of positive and negative sentinel node metastasis, we observed a statistically significant difference in two interleukins: The median of IL-2 levels in the negative group was 5.88 pg/ml compared to 32.57 pg/ml in the positive group (p=0.0005). The median of IL-6 levels in the negative group was 4.80 pg/ml compared to 32.02 pg/ml in the positive group (p=0.0048). CONCLUSION Interleukins IL-2, IL-6 and IL-10 are promising biomarkers of early-stage melanoma. IL-2 and IL-6 appear to be prognostic biomarkers.
Collapse
Affiliation(s)
- Radek Kucera
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Ondrej Topolcan
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Inka Treskova
- Department of Plastic Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Judita Kinkorova
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Jindra Windrichova
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Radka Fuchsova
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Sarka Svobodova
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Vladislav Treska
- Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Vaclav Babuska
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Jaroslav Novak
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Jiri Smejkal
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| |
Collapse
|
6
|
Kucera R, Topolcan O, Pecen L, Kinkorova J, Svobodova S, Windrichova J, Fuchsova R. Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic. Clin Chim Acta 2015; 444:271-7. [PMID: 25744488 DOI: 10.1016/j.cca.2015.02.036] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 02/20/2015] [Indexed: 10/23/2022]
Abstract
BACKGROUND IGF1 is responsible for regulation of growth, metabolism and differentiation of human cells. IGFBP3 is the most abundant of the carrier proteins for IGF1 in the blood. IGF1/IGFBP3 molar ratio is an indicator of IGF1 bioavailability. We decided to create a file of reference ranges of IGF1, IGFBP3 and IGF1/IGFBPP3 ratio for the adult Czech population across the age spectrum. METHODS We selected a group of 1022 subjects, 467 males and 555 females (ages 20-98 years), from several regions in the Czech Republic. The group consisted of blood donors and patients undergoing regular preventive examinations. Serum levels of IGF1 and IGFBP3 were measured using the following radioimmunoassay kits: IRMA IGF1 (Immunotech, Marseille, France) and IRMA IGFBP3 (Immunotech, Prague, Czech Republic). The IGF1/IGFBP3 ratio was also calculated. The following groups of patients were excluded: patients with diabetes, high blood glucose, high insulin levels, post-surgery patients, polymorbid patients, and subjects with oncological diseases. Subjects were divided into seven age-groups. Changes in the levels of observed analytes in each decade across the age spectrum were evaluated. All statistical analyses were performed by SAS 9.3 (Statistical Analysis Software release 9.3; SAS Institute Inc., Cary, NC, USA). RESULTS All three parameters IGF1, IGFBP3 and IGF1/IGFBP3 decreased in parallel with decrease in age: p<0.0001, r=-0.64, -0.35 and -0.54, respectively. The dynamics of the decline was different between males and females. Linear regression models with age as independent variable fitted by gender are displayed in Fig. 1. Non-parametric reference interval curves (medians and 2.5th-97.5th percentiles) for IGF1, IGFBP3 and IGF1/IGFBP3 ratio as function of age by gender are displayed in Fig. 2(a,b,c). All medians and 2.5th-97.5th percentiles were plotted by cubic spline. For males, linear regression models were as follows: IGF1=291.34619-2.41211 × age, IGFBP3=2931.62778-6.11659 × age, IGF1/IGFBP3=0.02897-0.00021213 × age. For females, we plotted the following: IGF1=241.67406-1.98466 × age, IGFBP3=3688.60561-16.39560 × age, IGF1/IGFBP3=0.02029-0.00013233 × age. IGF1 was statistically significantly higher in males with p<0.0001 (Wilcoxon test) but decreased faster (p=0.0121). IGFBP3 was statistically significantly higher in females with p=0.0004 (Wilcoxon test) but decreased faster (p<0.0001). IGF1/IGFBP3 was statistically significantly higher in males with p<0.0001 (Wilcoxon test) but decreased faster (p<0.0001). CONCLUSION Authors recommend using of a linear regression model based reference ranges for IGF1, IGFBP3 and IGF1/IGFBP3 ratio and using different reference ranges for genders.
Collapse
Affiliation(s)
- Radek Kucera
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic.
| | - Ondrej Topolcan
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic
| | - Ladislav Pecen
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic
| | - Judita Kinkorova
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic
| | - Sarka Svobodova
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic
| | - Jindra Windrichova
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic
| | - Radka Fuchsova
- Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic
| |
Collapse
|
7
|
|
8
|
Novak J, Zeman V, Matoulek M, Topolčan O, Svobodova Ś, Racek J, Kinkorova J. Optimalization of recovery, regeneration and rehabilitation. EPMA J 2014. [PMCID: PMC4125889 DOI: 10.1186/1878-5085-5-s1-a152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
9
|
Treska V, Skalicky T, Sutnar A, Vaclav L, Fichtl J, Kinkorova J, Vachtova M, Narsanska A. Prognostic importance of some clinical and therapeutic factors for the effect of portal vein embolization in patients with primarily inoperable colorectal liver metastases. Arch Med Sci 2013; 9:47-54. [PMID: 23515176 PMCID: PMC3598138 DOI: 10.5114/aoms.2013.33348] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Revised: 06/25/2011] [Accepted: 08/18/2011] [Indexed: 12/16/2022] Open
Abstract
INTRODUCTION Portal vein embolization (PVE) may increase the resectability of liver metastases. However, the problem of PVE is insufficient growth of the liver or tumor progression in some patients. The aim of this study was to evaluate the significance of commonly available clinical factors for the result of PVE. MATERIAL AND METHODS Portal vein embolization was performed in 38 patients with colorectal liver metastases. Effects of age, gender, time between PVE and liver resection, oncological therapy after PVE, indocyanine green retention rate test, synchronous, metachronous and extrahepatic metastases, liver volume before and after PVE, increase of liver volume after PVE and the quality of liver parenchyma before PVE on the result of PVE were evaluated. RESULTS Liver resection was performed in 23 (62.2%) patients within 1.3 ±0.4 months after PVE. Tumor progression occurred in 9 (23.7%) patients and 6 (15.8%) patients had insufficient liver hypertrophy. Significant clinical factors of PVE failure were number of liver metastases (cut-off - 4; odds ratio - 4.7; p < 0.03), liver volume after PVE (cut-off 1000 cm(3); odds ratio - 5.1; p < 0.02), growth of liver volume after PVE (cut-off 150 cm(3); odds ratio - 18.7; p < 0.002), oncological therapy administered concomitantly with PVE (p < 0.003). CONCLUSIONS Negative clinical factors of resectability of colorectal cancer liver metastases after PVE included more than four liver metastases, liver volume after PVE < 1000 cm(3), growth of the contralateral lobe by less than 150 cm(3) and concurrent oncological therapy.
Collapse
Affiliation(s)
| | - Tomas Skalicky
- University Hospital, School of Medicine, Pilsen, Czech Republic
| | - Alan Sutnar
- University Hospital, School of Medicine, Pilsen, Czech Republic
| | - Liska Vaclav
- University Hospital, School of Medicine, Pilsen, Czech Republic
| | - Jakub Fichtl
- University Hospital, School of Medicine, Pilsen, Czech Republic
| | | | - Monika Vachtova
- University Hospital, School of Medicine, Pilsen, Czech Republic
| | | |
Collapse
|